DIA Conference to Focus on Clinical Trial Disclosure and the Importance of Transparency
HORSHAM, Pa (PRWEB) September 10, 2013 -- The DIA conference Clinical Trial Disclosure: Towards a More Transparent World will provide guidance on potential implications of the transparency of clinical trial information in registration, reporting and more. The meeting, to be held Oct. 1 to 2 in Bethesda, Md., will bring together academics, government regulators and patient advocates to provide key guidance on:
• Requirements for clinical trial disclosure in the United States and the European Union
• The interaction among medical writing, regulatory affairs and clinical trial disclosure to maintain consistency for protocol registration and the reporting of results
• The impact of greater transparency in clinical trial disclosure on industry and academia
• The advantages and implications of the availability of clinical trial disclosure databases
“The continuing proliferation of national and industry-sponsored registries leaves many sponsors considering disclosure strategy, developing operational measures and looking for efficient ways to manage dissemination of clinical trial protocol information. We are excited to bring together these leaders to discuss moving the needle in clinical trial disclosures,” said Susan Cantrell, director of DIA North America.
Speakers include:
• Jarilyn Dupont, director of regulatory policy, Food and Drug Administration
• Mark Barnes, partner, Ropes & Gray LLP
• Chris Galvin, analyst, Office of Inspector General, U.S. Department of Health and Human Services
• Jessica B. Gilbart, president and CEO, DC/MD/VA Chapter, Lupus Foundation of America
• Christine Laine, M.D., editor, Annals of Internal Medicine, and senior vice president, American College of Physicians
• Joseph Solomon Ross, M.D., assistant professor of medicine (general medicine) and of public health (health policy), Yale School of Medicine
• Michael Krumenacker, M.D., publication compliance officer, Sanofi
To find out more about the event and to register, visit DIA’s website for Clinical Trial Disclosure: Towards a More Transparent World.
ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. Visit our website at http://www.diahome.org and follow DIA at: LinkedIn, Twitter, YouTube, Facebook, Flickr and Pinterest.
###
Eric Rosen, DIA, http://www.diahome.org, +1 (215) 290-9153, [email protected]
Share this article